Study Finds Aeruginascin Metabolite 4-HO-TMT is Active at the Serotonin 5-HT2A Receptor

Surprisingly, 4-HO-TMT has binding affinity similar to psilocin at 5-HT2A.


Researchers at CaaMTech, the University of Massachusetts Dartmouth, and Canopy Growth USA have published an article in ACS Omega detailing the synthesis, crystal structure, and serotonin receptor activity of 4-HO-TMT (4-hydroxy-N,N,N-trimethyltryptamine).1 This paper is the latest in a series of from CaaMTech that have come out since early 2019.2–10

Chadeayne et al. explained that their impetus for this study was gaining a better understanding of other potentially psychoactive molecules in magic mushrooms (aka psilocybin mushrooms) besides psilocin. They noted that the literature indicates the effects of magic mushrooms are different from pure psilocybin, suggesting a synergy such as what occurs between the compounds in cannabis.11,12 Chadeayne et al. stated, “The extracts of ‘magic mushrooms’ demonstrate the same clinical effects as pure psilocybin at dosages that are an order of magnitude smaller, suggesting important activity by other psychoactive molecules or the presence of an entourage effect.”

4-HO-TMT is purportedly the metabolite of aeruginascin, which is found in the magic mushroom Inocybe aeruginascens. The hypothesis about the origins of this metabolite is based on an analogy to the hydrolysis of the prodrug psilocybin to the active metabolite psilocin (Figure 1). Chadeayne et al. hypothesized that aeruginascin undergoes similar hydrolysis to form 4-HO-TMT.

Figure 1: Chemical structures showing the similarity that may exist between the conversion on the prodrug psilocybin to that of aeruginascin to its purported metabolite 4-HO-TMT.

Testing Hypotheses

4-HO-TMT has a similar chemical structure to bufotenidine, an active compound in toad venom (Figure 2). Bufotenidine is a strong selective agonist of the serotonin 5-HT3 receptor.13 As such, Chadeayne et al. worked from the hypothesis proposed by Jensen in 2004,  that 4-HO-TMT would show similar activity at 5-HT3.14

Figure 2: The chemical structures of 4-HO-TMT and bufotenidine.

The researchers also tested their prediction that 4-HO-TMT would be inactive at receptors in the serotonin 5-HT2 family. This idea stems from what the authors called “the leading hypothesis” in the scientific community on the activity of aeruginascin at these receptors.

Synthesis of 4-HO-TMT

The synthesis of 4-HO-TMT begins with 4-AcO-DMT (aka psilacetin, 4-acetoxy-N,N-dimethyltryptamine ) fumarate, a functional analog of psilocybin. Below are the basic synthesis steps described by Chadeayne et al.

  1. 4-AcO-DMT fumarate is methylated in the presence of excess iodomethane, resulting in 4-AcO-TMT (4-acetoxy-N,N,N-trimethyltryptammonium) iodide. Chadeayne et al. call this compound a functional analog of aeruginascin.
  2. 4-AcO-TMT iodide is hydrolyzed to 4-HO-TMT iodide in aqueous acetic acid.
  3. 4-HO-TMT iodide is purified by recrystallization in a methanolic solution.
  4. Both 4-HO-TMT and 4-AcO-TMT iodide salts were recrystallized from water to obtain their single-crystalline forms.

The authors report that,

These are the first two quaternary tryptammonium salts ever characterized by single-crystal diffraction.

They confirmed the identity and high purity of the compounds by using NMR and elemental analysis. Further, Chadeayne et al. solved the crystal structures of the iodide salts of 4-HO-TMT and 4-AcO-TMT. In a press release, CaaMTech refers to these compounds by the names Amphoria and Prophoria, respectively.

Serotonin Receptor Binding Affinity of 4-HO-TMT and 4-AcO-TMT

In the next part of the study, Chadeayne et al. tested the binding affinity of 4-HO-TMT and 4-AcO-TMT at four serotonin receptors, 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT3. Table 1 below shows the receptor testing data. For more information on receptor binding values and what they mean, see the PSR article Binding of Psilocin and Psilocybin to Serotonin Receptors.

Table 1: Ki values in nM for 4-HO-TMT and 4-AcO-TMT.1 Values for psilocybin and psilocin are included for comparison.15 Ki values >10,000 imply no activity at the receptor.


4-AcO-TMT showed no binding activity at any of the receptors tested. However, 4-HO-TMT had activity at 5-HT1A, 5-HT2A, and 5-HT2B. Agonist activity at 5-HT2A is regarded by experts as the hallmark of psychedelic activity.16

Although 4-HO-TMT showed less binding affinity at 5-HT2A than psilocin, the authors concluded that the Ki values were comparable (670.0 nM and 107.2 nM, respectively). Also, the data showed that 4-HO-TMT has a similar affinity for 5-HT2B compared to psilocybin.

Recall that one of the hypotheses Chadeayne et al. was testing was that aeruginascin’s active metabolite 4-HO-TMT would have an affinity for 5-HT3 like bufotenine. The data showed this was not the case. The Ki for 4-HO-TMT at 5-HT3 was >10,000 nM.

The authors also noted an important observation regarding the activity of 4-HO-TMT at the 5-HT2B receptor. In 2000, Rothman et al. proposed the involvement of 5-HT2B receptor activation with valvular heart disease (VHD).17 In the Chadeayne et al. study, the data indicated that 4-HO-TMT had significantly less binding affinity for 5-HT2B than psilocin. The comparison of Ki values is considered state of the art for estimating the safety of a compound in relation to 5-HT2B and VHD.18

Despite the value gained from these tests, it is unclear why Chadeayne et al. did not test the two compounds at nicotinic acetylcholine receptors. The results may have shed some light on the possible role of aeruginascin (or its metabolite) in the phenomenon known as wood lover paralysis.

What Does All This Mean for Psychedelic Research?

This study by Chadeayne et al. makes several significant contributions to the knowledge base of psychedelic science. First, it provides a synthesis method for 4-HO-TMT, which makes the compounds available for further research. Also, the crystal structures they resolved are essential for understanding changes at the molecular level that can affect the physical properties of a compound. From this, scientists can gain more understanding of the behavior of compounds at biological receptors.

Second, the receptor binding data was surprising based on what is known about the chemistry and pharmacology of similar compounds. Despite its close structural similarity to bufotenidine, 4-HO-TMT did not show an affinity for the 5-HT3 receptor. But surprisingly, 4-HO-TMT did have an affinity for the 5-HT2A receptor, showing a magnitude comparable to psilocin.

The latter results present an intriguing puzzle about the potential psychotropic activity of 4-HO-TMT. Chadeayne et al. say that by having a quaternary ammonium group, it appears unlikely that 4-HO-TMT could cross the blood-brain barrier (BBB) and directly affect 5-HT2A receptors in the brain. However, they point to a 2014 study indicating that another quaternary ammonium compound crosses the BBB.19 In this study, Zacny et al. showed that the compound known as methylnaltrexone or MTNX, crossed the BBB in humans, possibly via cellular transporters. Chadeayne et al. concluded,

therefore, psychotropic activity [of 4-HO-TMT] remains a possibility.

Summing up their explorations in psychedelic research thus far, CaaMTech CEO Dr. Andrew Chadeayne said,

Given the building momentum behind magic mushroom decriminalization and legalization, understanding all of the molecules in those mushrooms and their effects seems like a good idea.

Newest Most Voted
Inline Feedbacks
View all comments
Ezekiel Golan
3 months ago

totally unexpected. Must be scrutinized rigorously. But if consistent… INCREDIBLE

Andrew Chadeayne
3 months ago
Reply to  Ezekiel Golan

Yes – we were pretty surprised by the results. (We did reproduce them). Now we are eager to conduct some more follow up studies to get an even better understanding for what’s going on in magic mushrooms.

2 months ago

….and if these quaternaries are crossing the BBB. Cheers….

3 months ago

i wanted to know if there were any activity at the sigma receptors

Andrew Chadeayne
3 months ago
Reply to  james

Hi James – We will publish information about how these compounds act at other receptors soon. Right now, we still need to confirm some results. And, although some of our preliminary numbers are exciting, we want to be careful about only publishing good descriptions of reproducible data. In any event, thanks for your interest!

Del Potter
3 months ago

Absolutely Amazing.
There are so many possibilities here. My mind is reeling.

Andrew Chadeayne
3 months ago
Reply to  Del Potter

Thanks Del! Yes, what a wonderful time to be working in this space.

Enea May
2 months ago

Yeah, that pretty interesting.

2 months ago

Important research long overdue!!

  1. Chadeayne AR, Pham DNK, Reid BG, Golen JA, Manke DR. Active Metabolite of Aeruginascin (4-Hydroxy-N,N,N-trimethyltryptamine): Synthesis, Structure, and Serotonergic Binding Affinity. ACS Omega. Published online July 2, 2020. doi:10.1021/acsomega.0c02208
  2. Chadeayne AR, Golen JA, Manke DR. The Crystal Structure of 4-AcO-DMT Fumarate. Published online 2019.
  3. Chadeayne AR, Golen JA, Manke DR. Bis(4-acetoxy-N,N -dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug. Acta Crystallographica Section E Crystallographic Communications. 2019;75(6):900-902. doi:10.1107/S2056989019007370
  4. Chadeayne AR, Pham DNK, Golen JA, Manke DR. The fumarate salts of the N-isopropyl-N-methyl derivatives of DMT and psilocin. Acta Crystallographica Section E Crystallographic Communications. 2019;75(9):1316-1320. doi:10.1107/S2056989019011253
  5. Chadeayne AR, Pham DNK, Golen JA, Manke DR. Bis(4-hy­droxy-N,N-di-n-propyl­tryptammonium) fumarate tetrahydrate. IUCrData. 2019;4(11):x191469. doi:10.1107/S241431461901469X
  6. Chadeayne AR, Golen JA, Manke DR. N-Methyl-N-propyltryptamine (MPT). IUCrData. 2019;4(7):x190962. doi:10.1107/S2414314619009623
  7. Chadeayne AR, Pham DNK, Golen JA, Manke DR. Bis(4-hy­droxy-N-isopropyl-N-methyl­trypt­ammo­nium) fumarate: a new crystalline form of miprocin. Acta Cryst E. 2020;76(4):514-517. doi:10.1107/S2056989020002923
  8. Chadeayne AR, Pham DNK, Golen JA, Manke DR. Norpsilocin: freebase and fumarate salt. Acta Crystallographica Section E Crystallographic Communications. 2020;76(4):589-593. doi:10.1107/S2056989020004077
  9. Chadeayne AR, Pham DNK, Golen JA, Manke DR. 5-MeO-DALT: the freebase of N,N-diallyl-5-methoxytryptamine. IUCrData. 2020;5(4):x200498. doi:10.1107/S2414314620004988
  10. Chadeayne AR, Pham DNK, Golen JA, Manke DR. DMT analogues: N-ethyl-N-propyl­tryptamine and N-allyl-N-methytryptamine as their hydro­fumarate salts. Acta Cryst E. 2020;76(8):1201-1205. doi:10.1107/S2056989020008683
  11. Zhuk O, Jasicka-Misiak I, Poliwoda A, et al. Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice. Toxins. 2015;7(4):1018-1029. doi:10.3390/toxins7041018
  12. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344-1364. doi:10.1111/j.1476-5381.2011.01238.x
  13. Kilpatrick GJ, Bunce KT, Tyers MB. 5-HT3 receptors. Medicinal Research Reviews. 1990;10(4):441-475. doi:10.1002/med.2610100404
  14. Jensen N. Tryptamines as ligands and modulators of the serotonin 5‑HT 2A receptor and the Isolation of aeruginascin from the hallucinogenic mushroom Inocybe aeruginascens. Doctoral Thesis, Georg-August-Universität zu Göttingen, Göttingen, Germany. Published online 2004.
  15. Roth BL, Lopez E, Patel S, Kroeze WK. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? Neuroscientist. 2000;6(4):252-262. doi:10.1177/107385840000600408
  16. Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. Published online January 26, 2019:1. doi:10.1038/s41386-019-0324-9
  17. Rothman RB, Baumann MH, Savage Jason E., et al. Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications. Circulation. 2000;102(23):2836-2841. doi:10.1161/01.CIR.102.23.2836
  18. Papoian T, Jagadeesh G, Saulnier M, et al. Regulatory Forum Review: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations. Toxicol Pathol. 2017;45(3):381-388. doi:10.1177/0192623317690609
  19. Zacny JP, Wroblewski K, Coalson DW. Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers. Psychopharmacology. 2015;232(1):63-73. doi:10.1007/s00213-014-3637-8